ABSI vs LLY

Absci's score has been significantly downgraded due to material deterioration in its financial performance and a major clinical setback. The Q4 2025 earnings miss was substantial, with full-year 2025 revenue declining 38% YoY, signaling a clear operational stumble. Furthermore, the explicit halting of the ABS-101 program due to disappointing Phase 1 data is a critical blow to its internal pipeline...

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...